Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.

After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.

Additional Chinese coronavirus vaccine makers are now building up capacity, with Beijing-based AIM Vaccine preparing for a 400 million dose per year production capability for mRNA vaccines, while Chengdu-based Clover is to supply up to 414 million doses of its vaccines to GAVI.

Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.